The antibiotics most commonly used against gram-negative bacilli fall into a handful of major classes: beta-lactams (including penicillins, cephalosporins, carbapenems, and the monobactam aztreonam), fluoroquinolones, aminoglycosides, and polymyxins. Which drug gets chosen depends on where the infection is, how sick the patient is, and what the local resistance patterns look like. That last factor has become the dominant concern in recent years, because gram-negative bacteria have a structural advantage that makes them inherently harder to kill than their gram-positive counterparts, and resistance genes are spreading fast enough to outpace the development of new drugs.
What Makes Gram-Negative Bacilli So Difficult to Treat
Gram-negative bacteria have a double-layered cell envelope. The inner membrane is surrounded by a thin layer of cell wall material, and then there is a second, outer membrane that gram-positive bacteria simply do not have. The outer leaflet of that outer membrane is made up of lipopolysaccharide (LPS), a densely packed layer of molecules whose saturated fatty acid chains restrict how easily hydrophobic compounds can slip through.1npj Antimicrobials and Resistance. Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens This barrier acts as a built-in filter, and it is the reason many antibiotics that work well against gram-positive organisms are useless against gram-negatives. To get inside, a drug either has to be small and water-soluble enough to pass through protein channels called porins, or it has to interact directly with the outer membrane itself. That structural hurdle shapes every antibiotic choice clinicians make for these infections.
Beta-Lactams and Their Subdivisions
Beta-lactams are the largest and most commonly prescribed antibiotic family for gram-negative infections. They all work the same basic way: they bind to enzymes called penicillin-binding proteins (PBPs), which are responsible for the final cross-linking step in bacterial cell wall construction.2PubMed Central. Beta-lactam antibiotics induce a lethal malfunctioning of the bacterial cell wall synthesis machinery Block those enzymes and the bacterium cannot maintain its wall, leading to swelling and death.3PubMed. A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis Within this family, there is a clear hierarchy of spectrum and potency:
- Aminopenicillins: Ampicillin and amoxicillin are the narrowest options. They cover some community-acquired E. coli and similar organisms but are easily defeated by common resistance enzymes. Adding a beta-lactamase inhibitor like clavulanic acid (amoxicillin-clavulanate) broadens their reach.
- Antipseudomonal penicillins: Piperacillin-tazobactam is a workhorse for hospital-acquired infections. Tazobactam protects piperacillin from many beta-lactamase enzymes, giving it activity against a wider range of gram-negatives including many Pseudomonas aeruginosa strains.
- Cephalosporins: These range from first-generation agents with modest gram-negative coverage to third-generation drugs like ceftriaxone and ceftazidime with much broader activity, and fourth-generation cefepime, which adds stability against certain resistance enzymes.
- Carbapenems: Meropenem, imipenem, ertapenem, and doripenem sit at the top of the beta-lactam hierarchy. They resist most common beta-lactamase enzymes and are often reserved for serious infections caused by resistant organisms.
- Monobactams: Aztreonam is the lone member of this subclass. It has a narrow spectrum focused on gram-negative aerobes and has a unique structural feature: it is the only beta-lactam that is not broken down by metallo-beta-lactamases, a clinically important resistance enzyme family.4PubMed Central. Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates
Fluoroquinolones
Ciprofloxacin, levofloxacin, and their relatives work by a completely different mechanism than beta-lactams. They target two enzymes, DNA gyrase and topoisomerase IV, that bacteria need to manage the coiling and uncoiling of their DNA during replication. Fluoroquinolones lock these enzymes onto the DNA strand while it is broken, preventing the break from being resealed and effectively shredding the chromosome.5PubMed Central. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding This makes them bactericidal and fast-acting.
Fluoroquinolones are attractive for gram-negative infections because they are well absorbed orally, achieve good tissue concentrations, and cover a wide range of species. They have been a go-to choice for urinary tract infections, respiratory infections, and intra-abdominal infections for decades. However, their use has come under increasing scrutiny. Regulatory agencies have issued safety warnings about serious side effects including tendon damage, nerve problems, and mood changes, prompting guidelines that now recommend reserving fluoroquinolones for situations where safer alternatives are not available.6PubMed Central. Overview of Side-Effects of Antibacterial Fluoroquinolones: New Drugs versus Old Drugs, a Step Forward in the Safety Profile? Resistance has also climbed steeply. Part of that resistance spreads on plasmids, small loops of DNA that bacteria share freely. Plasmid-carried genes produce proteins that physically shield DNA gyrase from the drug, and one variant of a common enzyme can even chemically modify the fluoroquinolone molecule itself.7PubMed Central. Plasmid-mediated quinolone resistance
Aminoglycosides
Gentamicin, tobramycin, and amikacin are aminoglycosides, a class that kills gram-negative bacteria by binding to ribosomes and causing the cell to produce faulty proteins. They are concentration-dependent killers, meaning a single high dose can be more effective than spreading the same amount over several smaller doses. In practice, aminoglycosides are most often used in combination with a beta-lactam, particularly in life-threatening infections like sepsis, where adding an aminoglycoside or a fluoroquinolone to a beta-lactam has been linked to higher rates of appropriate initial coverage compared to using a beta-lactam alone.8PubMed Central. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis
The trade-off with aminoglycosides is toxicity. They can damage the kidneys by accumulating in the cells of the proximal tubule, and they can harm the inner ear’s hair cells through oxidative stress, causing hearing loss that may be irreversible.9PubMed. Aminoglycoside-Related Nephrotoxicity and Ototoxicity in Clinical Practice: A Review of Pathophysiological Mechanism and Treatment Options Risk rises with prolonged courses and in patients with impaired kidney function. That toxicity profile is a key reason aminoglycosides are rarely used as monotherapy for systemic infections today. For lung infections in cystic fibrosis patients, inhaled formulations of tobramycin deliver high concentrations directly to the airways while limiting how much drug reaches the bloodstream, reducing systemic side effects.10PubMed Central. Current and Emerging Inhaled Antibiotics for Chronic Pulmonary Pseudomonas aeruginosa and Staphylococcus aureus Infections in Cystic Fibrosis
Polymyxins as a Last Line
Colistin (polymyxin E) and polymyxin B occupy a unique niche. They target the LPS layer that makes gram-negative bacteria so hard to penetrate in the first place, displacing the stabilizing metal ions that hold LPS molecules together. Research in E. coli has shown that colistin disrupts the LPS in both the outer membrane and the inner cytoplasmic membrane, ultimately causing the cell to burst.11eLife. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane Polymyxins were largely abandoned in the 1970s and 1980s because of kidney toxicity, but the rise of extensively drug-resistant gram-negatives forced their revival. They are now used as salvage therapy for infections that have exhausted all other options, particularly carbapenem-resistant Acinetobacter baumannii and some Pseudomonas and Klebsiella strains.
Why Resistance Keeps Winning
Gram-negative bacilli have an unusually diverse toolkit for evading antibiotics, and three main mechanisms often work together in the same organism.
The most clinically consequential is enzyme production. Beta-lactamase enzymes chew up beta-lactam antibiotics before they can reach their targets. Extended-spectrum beta-lactamases (ESBLs) knock out most penicillins and cephalosporins. Carbapenemases go further, destroying even carbapenems. In Klebsiella pneumoniae, the two most common carbapenemase families are KPC (a serine-based enzyme) and NDM (a metallo-beta-lactamase that uses zinc).12PubMed Central. Co-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant Klebsiella Pneumoniae Clinical Isolate: Genetic Insights and Risks The genes for these enzymes frequently ride on plasmids, which means they can jump between species in hours. Carbapenem resistance is now a global public health problem, with outbreaks occurring worldwide and treatment options shrinking dramatically when these enzymes appear.13PubMed Central. Carbapenem resistance: overview of the problem and future perspectives
Beyond enzymes, gram-negatives use efflux pumps, molecular machinery that actively pushes antibiotics back out of the cell before they reach lethal concentrations. Pseudomonas aeruginosa is especially adept at this strategy, deploying four major efflux pump systems that can each handle multiple drug classes at once.14PubMed Central. Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa A third mechanism involves shutting down porins, the channels that water-soluble antibiotics use to enter the cell. When Pseudomonas reduces production of the porin OprD, carbapenems lose their route of entry. Studies of carbapenem-resistant Pseudomonas isolates have found that reduced OprD expression and increased efflux pump activity frequently occur together and correlate with the presence of carbapenemase enzymes as well.15Gene Reports. Expression of MexAB-OprM efflux pump and OprD porin in carbapenemase producing Pseudomonas aeruginosa clinical isolates This layering of resistance mechanisms explains why some hospital-acquired gram-negative infections are resistant to nearly everything.
A snapshot of how bad things can get comes from a study of carbapenem-resistant isolates at hospitals in Poland. Every single K. pneumoniae isolate tested was resistant to all penicillins, cephalosporins, and the fluoroquinolone levofloxacin; upwards of 96% resisted carbapenems. Among E. coli isolates, resistance was total across penicillins, cephalosporins, carbapenems, fluoroquinolones, and trimethoprim-sulfamethoxazole. A. baumannii showed complete carbapenem resistance, and P. aeruginosa was resistant to all tested carbapenems with additional high resistance rates to cephalosporins and fluoroquinolones.16Multidisciplinary Digital Publishing Institute (MDPI). Carbapenem-Resistant Gram-Negative Fermenting and Non-Fermenting Rods Isolated from Hospital Patients in Poland—What Are They Susceptible to? These are worst-case isolates, not representative of all gram-negative infections, but they illustrate why newer drugs are desperately needed.
Newer Combinations and Strategies
The most important recent development has been pairing beta-lactam antibiotics with novel beta-lactamase inhibitors that can neutralize resistance enzymes the older inhibitors could not touch. Ceftazidime-avibactam is the flagship example. Avibactam inhibits KPC carbapenemases, ESBLs, and AmpC enzymes, and when combined with ceftazidime it dramatically improves activity against resistant Enterobacterales and multidrug-resistant Pseudomonas.17PubMed. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms The improvement in potency can be enormous, with minimum inhibitory concentrations dropping by up to a thousandfold against some beta-lactamase producers.18PubMed. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination
Ceftazidime-avibactam does have a gap: it does not cover metallo-beta-lactamases like NDM, because avibactam cannot inhibit them. That gap has driven interest in pairing avibactam with aztreonam instead. Aztreonam naturally resists metallo-beta-lactamases, and avibactam protects it from the ESBLs that often ride alongside NDM genes on the same plasmid. The combination has shown promising activity against pathogens carrying metallo-beta-lactamases.19PubMed. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam
A more radical design is cefiderocol, a cephalosporin that has been engineered to hijack the bacterium’s own iron-uptake machinery. The drug binds to iron and gets actively transported into the cell through iron channels, which is why it is often described as a “Trojan horse” antibiotic.20PubMed Central. The Development of Cefiderocol (S-649266), A Novel Siderophore Cephalosporin, in the Era of Multidrug-Resistant Gram-Negative Bacterial Infection Once inside, it attacks PBPs just like any other cephalosporin, but the active-transport entry route means it bypasses the porin restrictions and efflux pumps that defeat conventional drugs. Research in Pseudomonas has confirmed that iron transporter systems are the route of entry.21PubMed Central. Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa Cefiderocol is stable against all known classes of carbapenemases, making it one of the broadest-spectrum options available for extensively resistant gram-negatives.
How Clinicians Choose in Practice
Antibiotic selection for gram-negative infections is not a matter of picking the strongest drug available. It starts with the site of infection. For a straightforward urinary tract infection caused by E. coli, the first-line options are usually oral agents: nitrofurantoin, trimethoprim-sulfamethoxazole, or a fluoroquinolone if resistance patterns allow, with a beta-lactam like amoxicillin-clavulanate or ceftriaxone as alternatives.22PubMed Central. Antibiotic Profiling of E. coli Borne UTI Infection in Tertiary Healthcare Settings The rise of ESBL-producing E. coli has given new life to older drugs like nitrofurantoin and fosfomycin, which often retain activity against strains that are resistant to cephalosporins and fluoroquinolones.23Clinical Microbiology and Infection. Antibiotic management of urinary tract infections in the post-antibiotic era: a narrative review highlighting diagnostic and antimicrobial stewardship
For bloodstream infections, bioavailability matters. A retrospective comparison of oral step-down antibiotics for gram-negative bacteremia found that drugs with high oral bioavailability, such as levofloxacin, had treatment failure rates around 2%, while agents with moderate or low bioavailability saw failure rates several times higher.24Elsevier / Journal of Global Antimicrobial Resistance. Oral antibiotics for the treatment of Gram-negative bloodstream infections: A retrospective comparison of three antibiotic classes That finding has reinforced the preference for high-bioavailability oral agents when patients are stable enough to transition off IV therapy.
In sepsis and septic shock, the empiric regimen is driven by how likely the infecting organism is to be resistant, based on the patient’s risk factors, the probable source of infection, and the severity of illness.25PubMed Central. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance A combination like a carbapenem plus an aminoglycoside casts the widest net. In one large retrospective analysis, adding an aminoglycoside to a carbapenem increased the likelihood of appropriate initial therapy from roughly 90% to about 94%; pairing an aminoglycoside with piperacillin-tazobactam pushed appropriate coverage from about 80% to over 91%.8PubMed Central. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis Those percentage-point gains can be lifesaving when every hour of inappropriate therapy in sepsis raises the risk of death.
De-escalation and Stewardship
Starting broad is often necessary, but staying broad is the problem. Once culture results identify the organism and its susceptibilities, clinicians are expected to narrow the regimen, a practice called de-escalation. A study of nearly 2.8 million U.S. inpatients who received empiric gram-negative antibiotics in 2019 found that about half underwent de-escalation, while roughly 6.5% required escalation to a broader agent. The initial empiric choice was the single biggest factor in whether escalation or de-escalation occurred, accounting for over half the explained variation in those decisions.26PubMed Central. Clinical, contextual and hospital-level factors associated with escalation and de-escalation of empiric Gram-negative antibiotics among US inpatients
De-escalation sounds straightforward, but the practice is messier than the theory. Expert commentary has pointed out that while de-escalation is widely recommended as a way to reduce antibiotic pressure and curb resistance, clinical trials have not convincingly shown that it improves individual patient outcomes. There is also a paradox: de-escalation has been associated with longer total courses of antibiotics, and the expectation that “we can always de-escalate” may quietly encourage clinicians to start with unnecessarily broad regimens in the first place.27PubMed Central. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts The tension between getting the first antibiotic right and not overusing broad-spectrum drugs is the central challenge of gram-negative infection management, and it does not have a clean resolution.
When Porins and Pumps Matter More Than Enzymes
Resistance discussions tend to focus on beta-lactamases because they are dramatic and measurable, but in Pseudomonas aeruginosa the quieter mechanisms often matter just as much. Reduced porin expression and ramped-up efflux pumps can make a strain resistant to carbapenems without any carbapenemase enzyme at all. Both influx reduction and efflux upregulation frequently result from mutations in regulatory genes, meaning the bacterium does not need to acquire a new gene from elsewhere; it simply tweaks the ones it already has.28PubMed Central. Antibiotic influx and efflux in Pseudomonas aeruginosa: Regulation and therapeutic implications This is part of why Pseudomonas is one of the most consistently difficult gram-negative pathogens. Its intrinsic resistance floor is higher than most other species before any acquired resistance is layered on top, and drugs like cefiderocol that bypass porins entirely represent a fundamentally different approach to solving that problem.